Application of the murine anti-Gd-2 antibody 14.Gd-2a for diagnosis and therapy of neuroblastoma.

Abstract

We have tested the sialoganglioside monoclonal antibody Gd-2a for scintigraphic diagnostic and for immunotherapy in children with neuroblastoma stage IV. We could confirm tumor sites with Gd-2a scans in 1/2 children. Doses of 20-60 mg/m2 were administered daily for 5-10 days. 2/2 children with multiple tumor sites showed significant tumor regression. Four children, treated preventively, are still in clinical remission. One child showed tumor progression despite Gd-2a treatment. Adverse effects included itching, rashes, and pain.

• Authors: P Reuland, R Handgretinger, H Smykowsky, R Dopfer, T Klingebiel, B M Miller, R A Reisfeld, S Gallagher, E Koscelniak, J Treuner
• Journal: International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology (Int J Rad Appl Instrum B) Vol. 18 Issue 1 Pg. 121-5 ( 1991) ISSN: 0883-2897 [Print] England
• PMID: 2010296 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal
• Gangliosides
• Iodine Radioisotopes

Topics

• Adolescent
• Antibodies, Monoclonal (therapeutic use)
• Antibody-Dependent Cell Cytotoxicity (immunology)
• Child
• Child, Preschool
• Female
• Gangliosides (immunology)
• Humans
• Immunotherapy
• Iodine Radioisotopes (therapeutic use)
• Male
• Neuroblastoma (diagnostic imaging, immunology)
• Radionuclide Imaging